January 22, 2020 7:12pm

Pre-open indications: 3 HITs < sold into strength RENE.L (+$10.50) and MESO (+$0.43), RGNX (+$0.60) and 5 MISS < QURE (-$0.77), SAGE (-$1.43), BLUE (-$2.02), GBT (-$1.24) and AXGN (-$0.08) >

It’s an honor to be considered the “canary in the (sectors) coal mine”!  I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors in the perception of sector vulnerabilities and strengths – it’s more than opinion, the facts and truth need to be recognized!

 

The Dow closed DOWN -9.77 points (-0.03%), the S&P closed UP +0.96 points (-0.03%) and the NASDAQ closed UP +12.96 points (+0.14%)

 

Henry’omics:

Indexes ended a volatile session along the flatline on Wednesday.

When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started

Stocks are off to a strong start for the year; through 14 sessions, the S&P 500 has closed lower just five times and is up 2.8% <CNBC>.

 

Get ready for Q4 results and their potential effect of declines and sentiment. 

When in a "pickle", trust those who have insight into the mechanics of process!

 

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Wednesday the IBB closed down -0.17% and XBI closed down -0.22%
  • Tuesday the IBB closed down -1.17% and XBI closed down -1.56%
  • Monday markets were closed

 

The advance/decline line scenario of 35 covered companies:

  • Wednesday the close was positive with an A/D line of 18/17, 0 flat of 35 covered,
  • Tuesday the close was negative with an A/D line of 5/28, 2 flat of 35 covered,
  • Monday markets were closed,

 

Decliners:

  • Alnylam Pharmaceuticals (-$2.35);
  • bluebird bio (BLUE-$2.02 after Tuesday’s -$2.22);
  • Sage therapeutics (SAGE -$1.43 after Tuesday’s -$3.13);
  • Global Blood Therapeutics (GBT -$1.14 after Tuesday’s -$1.69, Friday’s -$3.44, Thursday’s +$1.52 and last Wednesday’s +$1.65);
  • uniQure (QURE -$0.77 after Tuesday’s -$5.36);

Incliners:

  • ReNeuron (RENE.L +$10.50 after Tuesday’s +$9.00 and Friday’s +$9.50);
  • Applied Genetic Technologies (AGTC +$1.61 after Tuesday’s +$0.09);
  • Ionis Pharmaceuticals (IONS +$1.21);
  • Regenxbio (RGNX +$o.60 after Tuesday’s -$1.93);
  • Mesoblast (MESO +$0.43 after Tuesday’s +$0.11 and Friday’s +$1.14);

 

The percentage (%) indicators:

  • Wednesday’s range of the 18 upside was +0.37% (EDIT) to +19.52% (AGTC) while the 17  downside ranged from -0.53% (SLDB) to -4.28% (CLBS); 
  • Tuesday’s range of the 5 upside was +0.71% (ADRO) to +5.96% (RENE.L) while the 28 downside ranged from -0.18% (IONS) to -8.94% (AXGN); 
  • Monday markets were closed;

 

Upside volume stats:  to compare

  • Wednesday: 5 out of the 18 upside had higher than the 3-month average volume;
  • Tuesday: 2 out of the 5 upside had higher than the 3 month average volume;
  • Monday markets were closed;

Downside volume stats:

  • Wednesday: 5 out of the 17 downside had higher than the 3-month average volume;
  • Tuesday: 12 out of the 28 downside had higher than the 3 month average volume;
  • Monday markets were closed;

 

0 flat

 

January’s sessions of 35 covered companies:

Wednesday closed POSITIVE with 17 decliners, 18 advancers and 0 flat;

Tuesday closed NEGATIVE with 28 decliners, 5 advancers and 2 flat;

Monday markets were closed

Friday closed NEGATIVE with 20 decliners, 14 advancers and 1 flat;

Thursday closed POSITIVE with 15 decliners, 18 advancers and 2 flats;

Wednesday closed POSITIVE with 14 decliners, 20 advancers and 1 flat;

Tuesday closed POSITIVE with 7 decliners, 28 advancers and 1 flat;

Thursday closed POSITIVE with 12 decliners, 22 advancers and 1 flat;

Wednesday closed POSITIVE with 10 decliners, 23 advancers and 2 flats;

Tuesday closed POSITIVE with 15 decliners, 22 advancers and 0 flat;

Monday closed POSITIVE with 13 decliners, 22 advancers and 0 flat;

Friday closed NEGATIVE with 19 decliners, 15 advancers and 1 flat;

Thursday closed NEGATIVE with 18 decliners, 15 advancers and 2 flats;

Wednesday markets were closed;

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.